FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OIVID APPROVAL								
OMB Number:	3235-0287							
Estimated ave	rage hurden							

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>King David John</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>aTYR PHARMA INC</u> [ LIFE ]					(Che	ck all application	able)	erson(s) to Issu 10% Ov	vner		
(Last) (First) (Middle) 3545 JOHN HOPKINS COURT SUITE 250			0.	3. Date of Earliest Transaction (Month/Day/Year) 02/06/2018						X Officer (give title Other (specify below)  Chief Scientific Officer					
(Street) SAN DII			92121 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. In Line					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Transa Date			Transaction ate Month/Day/	Execution Date,		Code (Ins	itr.		str. 3, 4 and 5	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	re Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		Code	ansaction Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Employee Stock Option (right to buy)	\$3.3	02/06/2018		A		150,000		(1)	02/06/2028	Common Stock	150,000	\$0.00	150,000	D	

## **Explanation of Responses:**

1. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2018, such that this option will be fully exercisable on February 6, 2022. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.

## Remarks:

Nancy D. Krueger, Attorney-In-02/08/2018

**Fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.